Literature DB >> 31422920

Cognitive function following a major depressive episode: a systematic review and meta-analysis.

Maria Semkovska1, Lisa Quinlivan2, Tara O'Grady2, Rebecca Johnson3, Aisling Collins2, Jessica O'Connor2, Hannah Knittle2, Elayne Ahern2, Taylor Gload4.   

Abstract

BACKGROUND: Substantial evidence suggests that cognitive deficits might persist after remission of a major depressive episode. However, results are inconsistent relative to the importance, pattern, severity, and moderating factors of this impairment. We aimed to determine how cognitive function following a major depressive episode compares with normal function, to specify the pattern and severity of persistent cognitive dysfunctions, and to examine the potential moderator effect of ten prespecified clinical and demographic variables.
METHODS: We did a systematic review and meta-analysis of the published research. We searched systematically MEDLINE, Embase, PsycARTICLES, PsycINFO, the Cochrane Library, and relevant reviews identified by our database search, for research published from Jan 1, 1972, up to Jan 31, 2018, for studies of patients with past depression. We included all independent studies of patients who were assessed while in remission from a major depressive episode with at least one cognitive test, with inclusion of a healthy control group assessed with either the same test(s) as the major depressive episode group or with a standardised test with published age-stratified normative data. The main outcome was the difference in cognitive performance between major depressive episode remitters and healthy controls. Effect sizes were calculated using random-effects models for cognitive outcomes classified into 18 standard domains. Moderators of between-study variability were assessed using mixed-effects subgroup analyses and meta-regressions.
FINDINGS: Of 10 126 citations identified by our search, 75 cognitive variables from 252 eligible studies (11 882 major depressive episode remitters and 8533 healthy controls) were included in our meta-analysis. Significant deficits following major depressive episode remission were observed in 55 (73%) of the 75 cognitive variables. These deficits (in the domains of processing speed, visual selective attention, working memory, verbal learning, and executive functioning), were generally small (30 [40%] of the 75 variables) or medium (22 [29%]) in size, although three long-term memory variables showed large deficits: g=-0·81 [95% CI -1·01 to -0·61] for logical memory immediate recall, g=-0·88 [-1·19 to -0·57] for logical memory delayed recall, and g=-0·84 [-1·18 to -0·50] for Cambridge Neuropsychological Test Automated Battery pattern recognition latency. Auditory attention, general autobiographical memory, inhibition ability unconstrained by speed, and intellectual functioning unconstrained by speed were equivalent between major depressive episode remitters and matched controls. The number of previous depressive episodes explained heterogeneity in the majority of variables (z=-2·06 [p=0·039] to z=-4·26 [p<0·0001]).
INTERPRETATION: Deficits in selective attention, working memory, and long-term memory persist in remission from a major depressive episode and worsen with repeated episodes. Depression treatments, including relapse prevention, need to target these cognitive functions to optimise prognosis. FUNDING: None.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31422920     DOI: 10.1016/S2215-0366(19)30291-3

Source DB:  PubMed          Journal:  Lancet Psychiatry        ISSN: 2215-0366            Impact factor:   27.083


  55 in total

1.  Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram.

Authors:  Marina Sagud; Matea Nikolac Perkovic; Anja Dvojkovic; Nenad Jaksic; Bjanka Vuksan-Cusa; Maja Zivkovic; Zorana Kusevic; Alma Mihaljevic-Peles; Nela Pivac
Journal:  Psychopharmacology (Berl)       Date:  2021-02-09       Impact factor: 4.530

2.  Fast-acting antidepressant-like effects of Reelin evaluated in the repeated-corticosterone chronic stress paradigm.

Authors:  Hector J Caruncho; Lisa E Kalynchuk; Kyle J Brymer; Jenessa Johnston; Justin J Botterill; Raquel Romay-Tallon; Milann A Mitchell; Josh Allen; Graziano Pinna
Journal:  Neuropsychopharmacology       Date:  2020-01-11       Impact factor: 7.853

Review 3.  Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders.

Authors:  Thomas Prévot; Etienne Sibille
Journal:  Mol Psychiatry       Date:  2020-04-28       Impact factor: 15.992

4.  Functional status and return to work in people with major depression: a 3-year national follow-up study.

Authors:  Yu-Chen Chiang; Tsan-Hon Liou; Jia-Pei Hong; Chih-Hong Lee; Yu-Hao Lee; Reuben Escorpizo
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2022-02-12       Impact factor: 4.328

5.  Investigating whether depressed youth exhibiting elevated C reactive protein perform worse on measures of executive functioning, verbal fluency and episodic memory in a large, population based sample of Dutch adolescents.

Authors:  Naoise Mac Giollabhui; Lauren B Alloy; Catharina A Hartman
Journal:  Brain Behav Immun       Date:  2020-09-02       Impact factor: 7.217

6.  Association of Chemokine (C-C Motif) Receptor 5 and Ligand 5 with Recovery from Major Depressive Disorder and Related Neurocognitive Impairment.

Authors:  Olivia Bauer; Vladimir M Milenkovic; Sven Hilbert; Nina Sarubin; Johannes Weigl; Lisa-Marie Bahr; Thomas C Wetter; Barbara Heckel; Christian H Wetzel; Rainer Rupprecht; Caroline Nothdurfter
Journal:  Neuroimmunomodulation       Date:  2021-01-27       Impact factor: 2.492

7.  Prevalence of Depression and Associated Factors Among Quarantined Individuals During the COVID-19 Pandemic in Tigrai Treatment and Quarantine Centers, Tigrai, Ethiopia, 2020: A Cross-Sectional Study.

Authors:  Haftamu Mamo Hagezom; Ataklti Berhe Gebrehiwet; Mekonnen Haftom Goytom; Embaye Amare Alemseged
Journal:  Infect Drug Resist       Date:  2021-06-04       Impact factor: 4.003

8.  Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.

Authors:  Trisha Chakrabarty; Shane J McInerney; Ivan J Torres; Benicio N Frey; Roumen V Milev; Daniel J Müller; Susan Rotzinger; Sidney H Kennedy; Raymond W Lam
Journal:  CNS Drugs       Date:  2021-03-08       Impact factor: 5.749

9.  Relationship Between Depression/Anxiety and Cognitive Function Before and 6 Weeks After Major Non-Cardiac Surgery in Older Adults.

Authors:  Deborah M Oyeyemi; Mary Cooter; Stacey Chung; Heather E Whitson; Jeffrey N Browndyke; Michael J Devinney; Patrick J Smith; Grant E Garrigues; Eugene Moretti; Judd W Moul; Harvey Jay Cohen; Joseph P Mathew; Miles Berger
Journal:  J Geriatr Psychiatry Neurol       Date:  2020-12-30       Impact factor: 2.680

10.  The Effects of Repetitive Transcranial Magnetic Stimulation Antidepressant Response on Cold Cognition: A Single-Arm Prospective Longitudinal Study.

Authors:  Helene Janine Hopman; Hiu Ying Choy; Wing Sze Ho; Hanna Lu; Wing Ho Oscar Wong; Sau Man Sandra Chan
Journal:  Neuropsychiatr Dis Treat       Date:  2021-05-26       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.